Takeda Biopharmaceuticals India Profile
Key Indicators
- Authorised Capital ₹ 265.01 Cr
- Paid Up Capital ₹ 215.51 Cr
- Company Age 9 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 0.36%
- Profit Growth 39.53%
- Ebitda 68.43%
- Net Worth 5.99%
- Total Assets -12.25%
About Takeda Biopharmaceuticals India
Takeda Biopharmaceuticals India Private Limited (TBIPL) is a Private Limited Foreign Company Incorporated In India incorporated in India on 15 April 2015 (Nine years and ten months 0 days old ). Its registered office is in Gurgaon, Haryana, India.
The Corporate was formerly known as Baxalta Bioscience India Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 265.01 Cr and a paid-up capital of Rs 215.51 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Takeda Biopharmaceuticals India Private Limited India is Gunjan Malhotra as COMPANY SECRETARY. Gopal Agrawal, Serina Fischer, and Anoop Kamat serve as directors at the Company.
Company Details
-
Location
Gurgaon, Haryana, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U51909HR2015FTC055144
-
Company No.
055144
-
Company Classification
Private Limited Foreign Company Incorporated In India
-
Incorporation Date
15 Apr 2015
-
Date of AGM
01 Dec 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Takeda Biopharmaceuticals India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gunjan Malhotra
|
Company Secretary | 05-Jul-2016 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Gopal Agrawal
|
Director | 08-Aug-2019 | Current |
Serina Fischer
|
Director | 15-Mar-2022 | Current |
|
Anoop Kamat
|
Director | 23-Apr-2021 | Current |
Financial Performance of Takeda Biopharmaceuticals India.
Takeda Biopharmaceuticals India Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.36% increase. The company also saw a substantial improvement in profitability, with a 39.53% increase in profit. The company's net worth moved up by a moderate rise of 5.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Takeda Biopharmaceuticals India?
In 2023, Takeda Biopharmaceuticals India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Takeda Biopharmaceuticals India?
Takeda Biopharmaceuticals India has a workforce of 195 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Takeda Biopharmaceuticals India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Takeda Biopharmaceuticals India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
